Core Insights - Damora Therapeutics is on track to submit an Investigational New Drug (IND) or Clinical Trial Application (CTA) for its lead program DMR-001 by mid-2026, targeting mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF) [2][6] - The company reported a strong financial position with approximately $535 million in cash and cash equivalents as of February 28, 2026, which is expected to fund operations into Phase 3 development of DMR-001 [1][4] - The net loss for the year ended December 31, 2025, was $209.8 million, significantly higher than the $21.4 million loss reported for 2024, primarily due to acquired in-process research and development costs [8][15] Financial Performance - Cash and cash equivalents were approximately $257.6 million as of December 31, 2025, and increased to $535 million following a public offering in February 2026 [4][13] - Research and development expenses rose to $26.9 million for the year ended December 31, 2025, compared to $6.4 million in 2024, driven by increased clinical trial-related expenses and other R&D costs [5][15] - General and administrative expenses decreased to $9.7 million in 2025 from $10.5 million in 2024, mainly due to reduced stock-based compensation costs [7][15] Corporate Developments - The acquisition of Damora Therapeutics was completed in November 2025, adding a pipeline of therapies targeting mutCALR-driven myeloproliferative neoplasms [6] - The leadership team was strengthened with the appointment of Sherwin Sattarzadeh as COO and Becker Hewes, M.D. as CMO in January 2026 [6] - The company changed its name to Damora Therapeutics, Inc., with its common stock trading on Nasdaq under the ticker symbol "DMRA" starting March 2026 [6] Upcoming Milestones - DMR-001 IND or CTA submission is expected in mid-2026, with two clinical proof-of-concept datasets anticipated beginning mid-2027 [1][6] - DMR-002 IND or CTA submission is expected in the second half of 2026, and DMR-003 submission is anticipated in 2027 [6]